J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology

Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.

Business report

Johnson & Johnson’s pharmaceutical sales have been above-market for the past seven years and the firm plans to maintain that trend, largely on the continued strength of its oncology and immunology portfolios. J&J execs explained during a pharmaceuticals business review how recent launches and line extensions will allow it to deliver that growth.

Oncology is becoming an increasingly important therapeutic area for J&J, and along with the more established immunology business, is one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip